Helping young people who inject drugs start treatment for Hepatitis C

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a behavioral intervention designed to increase the initiation of Hepatitis C treatment among young adults who inject drugs. It involves a randomized controlled trial with 250 participants, including individuals diagnosed with Hepatitis C and their primary injecting partners. The intervention consists of two sessions aimed at providing support and resources to encourage treatment initiation, compared to standard care. The study focuses on young people aged 18-30 to address a critical gap in treatment uptake within this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Self report injecting drugs in the past month
* Self report a primary injecting partner (currently inject drugs together)
* HCV infection identified at partnering community-based clinical site

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Meghan D Morris, MPH, PhD — University of California, San Francisco
• Study coordinator: Meghan D Morris, MPH, PhD
• Email: meghan.morris@ucsf.edu
• Phone: 415-574-0651

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV

  This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.

  Recruiting at 8 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 9 other locations · NCT07040319

• Evaluating hepatitis C treatment during pregnancy

  This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.

  Recruiting at 2 sites Washington University School of Medicine · St Louis, Missouri and 1 other locations · NCT06367465

• Decentralized treatment for hepatitis C in Brazil

  This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.

  Recruiting at 2 sites Phase 4 Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro and 1 other locations · NCT06306300

• Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania

  This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.

  Recruiting Early Phase 1 Médecins du Monde · Yerevan · NCT06159504

• Point-of-care testing program for Hepatitis C screening

  This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.

  Recruiting at 6 sites Kirby Institute · Canberra, Australian Capital Territory and 12 other locations · NCT05713136

• Screening for hepatitis B, hepatitis C and HIV using a dried blood spot

  This project will try a simple dried blood spot test to check people who use drugs for hepatitis B, hepatitis C and HIV.

  Recruiting at 11 sites University Hospital, Rouen · Avranches and 10 other locations · NCT05390424

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.